NTRK Fusion-positive Non-small-cell Lung Cancer: The Diagnosis and Targeted Therapy.
暂无分享,去创建一个
[1] P. Jänne,et al. U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors , 2020, Clinical Cancer Research.
[2] A. Markham. Tepotinib: First Approval , 2020, Drugs.
[3] M. Ladanyi,et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. , 2020, The Lancet. Oncology.
[4] A. Drilon,et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.
[5] M. Ladanyi,et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] Kengo Watanabe,et al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models , 2019, Nature Communications.
[7] S. Keam,et al. Entrectinib: First Global Approval , 2019, Drugs.
[8] A. Zehir,et al. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy , 2019, The Journal of molecular diagnostics : JMD.
[9] F. Penault-Llorca,et al. Testing algorithm for identification of patients with TRK fusion cancer , 2019, Journal of Clinical Pathology.
[10] Jessica L. Davis,et al. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] W. Sellers,et al. Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation , 2019, Clinical Cancer Research.
[12] A. Jemal,et al. Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[13] A. Drilon,et al. NTRK fusion-positive cancers and TRK inhibitor therapy , 2018, Nature Reviews Clinical Oncology.
[14] J. Swensen,et al. Molecular characterization of cancers with NTRK gene fusions , 2018, Modern Pathology.
[15] A. Drilon,et al. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. , 2018, Cancer discovery.
[16] D. Hong,et al. Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins , 2018, Clinical Cancer Research.
[17] C. Fletcher,et al. Evaluation of pan‐TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis‐like neural tumour and histological mimics , 2018, Histopathology.
[18] Jessica L. Davis,et al. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors , 2018, The American journal of surgical pathology.
[19] Funda Meric-Bernstam,et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.
[20] M. Ladanyi,et al. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions , 2017, The American journal of surgical pathology.
[21] B. Taylor,et al. A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. , 2017, Cancer discovery.
[22] A. Drilon,et al. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance , 2017, Nature Reviews Clinical Oncology.
[23] F. Meric-Bernstam,et al. Targeting TRK family proteins in cancer , 2017, Pharmacology & therapeutics.
[24] H. Groen,et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. , 2016, The Lancet. Oncology.
[25] A. Isacchi,et al. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor. , 2016, Journal of medicinal chemistry.
[26] A. Sartore-Bianchi,et al. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types , 2016, ESMO Open.
[27] E. Giovannetti,et al. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor , 2015, Expert opinion on investigational drugs.
[28] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[29] Jeffrey W. Clark,et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[30] Nicolas Stransky,et al. The landscape of kinase fusions in cancer , 2014, Nature Communications.
[31] William Pao,et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.
[32] T. Vaněček,et al. Mammary Analogue Secretory Carcinoma of Salivary Glands With High-grade Transformation: Report of 3 Cases With the ETV6-NTRK3 Gene Fusion and Analysis of TP53, &bgr;-Catenin, EGFR, and CCND1 Genes , 2014, The American journal of surgical pathology.
[33] L. Garraway,et al. Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer , 2013, Nature Medicine.
[34] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[35] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[36] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[37] A. Joe,et al. Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy , 2006, Nature Clinical Practice Oncology.
[38] I. Screpanti,et al. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. , 2004, Cancer cell.
[39] Combating Acquired TRK Inhibitor Resistance. , 2019, Cancer discovery.
[40] H. Groen,et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. , 2016, The Lancet. Oncology.
[41] R. Doebele,et al. TRKing down an old oncogene in a new era of targeted therapy. , 2015, Cancer discovery.
[42] C. Gomez-Fernandez,et al. Searching for mammary analog secretory carcinoma of salivary gland among its mimics , 2014, Modern Pathology.
[43] S. Skaper. The neurotrophin family of neurotrophic factors: an overview. , 2012, Methods in molecular biology.
[44] E. Huang,et al. Neurotrophins: roles in neuronal development and function. , 2001, Annual review of neuroscience.